Illumina, Inc.

Healthcare · Medical - Diagnostics & Research

Overall research band Mixed

Quality Mixed

Valuation Weak

Balance sheet Weak

Market confirmation Exceptional

One-minute company read

What this report can tell you now

What the company does

Illumina, Inc. delivers advanced genetic and genomic analysis tools, focusing on sequencing and array technologies. Its main products include specialized instrumentation, consumables for genetic analysis, and comprehensive genotyping and sequencing services. The company also provides instrument maintenance agreements, collaborates through development and licensing deals, and performs cancer detection tests. Illumina serves a diverse customer base, including genomic research facilities, universities, government laboratories, medical centers, pharmaceutical and biotechnology companies, molecular diagnostic providers, and consumer genomics businesses. Revenue is generated through direct sales and partnerships with life-science distributors across North America, Europe, Latin America, the Asia-Pacific, the Middle East, and Africa.

The current research profile is Mixed Setup, with strong market confirmation. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

Recent market behavior is the strongest visible confirmation. Check whether it agrees with the underlying business evidence.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

Read the latest filing or company update.
Check the financial period behind each metric.
Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC17.5%Model input; read with the evidence status and period context.

Operating margin19.9%Model input; read with the evidence status and period context.

Revenue CAGR · 4 years-1.1%Model input; read with the evidence status and period context.

FCF margin21.5%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.

Evidence detailSee exact inputs, source context, and model-aware metrics.

HistoryReview score and research changes over time.

MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.